Amylyx (AMLX) Climbs to Fresh High as Avexitide Moves Closer to Commercialization

Amylyx Pharmaceuticals Inc. shares climbed to a fresh three-year high on Tuesday, reaching an intraday peak of $35.39 before closing at $35.11, representing a gain of 63.84 percent for the session. The rally followed positive phase 3 clinical trial results for Avexitide, the company’s investigational treatment for post-bariatric hypoglycemia, a chronic metabolic condition affecting approximately 8 percent of the U.S. population.
In the clinical study involving 78 participants, Avexitide s